@article{e429baaf0db644449b6f0ef797f518e7,
title = "Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis",
keywords = "antithrombotic therapy, atrial fibrillation, coronary stenting",
author = "Mitsuru Ishii and Masaharu Akao and Satoshi Yasuda and Koichi Kaikita and Junya Ako and Tetsuya Matoba and Masato Nakamura and Katsumi Miyauchi and Nobuhisa Hagiwara and Kazuo Kimura and Atsushi Hirayama and Kunihiko Matsui and Hisao Ogawa",
note = "Funding Information: The Japan Cardiovascular Research Foundation conducted the trial using funds provided by Bayer Yakuhin, Ltd. These funds were provided without restrictions or requirements. Mebix, Inc, for their contribution in the selection of the participating centers; in the supervision or monitoring of the centers; in collecting trial data; in storing trial data; in data analysis of the trial results, and in the provision of editorial assistance with the preparation of the manuscript under the guidance of authors, were financed by the Japan Cardiovascular Research Foundation based on funds received from Bayer Yakuhin, Ltd. This work was supported by the Japan Cardiovascular Research Foundation based on a contract with Bayer Yakuhin, Ltd., who had no role in the design of the trial, collection or analysis of the data, interpretation of the trial results, or writing of the manuscript.",
year = "2022",
doi = "10.1161/JAHA.122.027107",
language = "English",
volume = "11",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "21",
}